Scotland exposes aesthetic data gap

Scotland supplied the week's only material development. Two government FOI releases explain why the country cannot produce consistent national data on complications from non-surgical aesthetic procedures.

We check six sources every week. When something changes, we cover it. When it does not, we say so. That is the point.

CQC — no new target-sector guidance

No change. A review of the CQC news listing through 26 July found no new guidance directed at independent doctors, private clinics or aesthetic providers.

Already covered: Our CQC chair update examines what Sir Mike Richards' regulatory record may mean for clinics.

ASA — no new target-sector ruling

No change. A review of the ASA rulings listing through 26 July found no formal ruling after the prior scan involving private clinics, cosmetic procedures, weight-loss medicines, online pharmacies, botulinum toxin or another prescription-only medicine.

Already covered: The recurring compliance pattern is set out in our weight-loss advertising enforcement report and POM advertising guide.

GPhC — no new target-sector update

No change. A review of the GPhC news and updates listing through 26 July found no new target-sector publication after the prior scan.

Already covered: Our analysis of the GPhC weight-management review explains the regulator's findings on risk assessments and BMI checks in online pharmacy services.

DHSC licensing — timetable unchanged

No change. The published consultation response remained the latest substantive DHSC update reviewed on England's non-surgical cosmetic-procedures licensing scheme. It contains no later timetable or scheme-design announcement.

Already covered: Read the complete UK cosmetic-procedure licensing guide and our Section 180 explainer.

Scotland — the missing complications data

Changed. On 24 July, the Scottish Government published two closely overlapping FOI releases about adverse events from non-surgical aesthetic procedures and SP Bill 77.

• The Government said it does not hold all the requested Scotland-specific information.
• Because the sector has largely been unregulated, consistent or comprehensive data on complications, adverse events and deaths has not been available.
• NHS coding records the condition treated, but not why treatment was required. That prevents the requested complications dataset from being assembled.
• Among 329 Scotland-based medical respondents to an attached survey, 114 — 35% — said they had treated patients who needed care after complications from unregulated cosmetic procedures.
• Of those 114 respondents, 98 — 86% — said the annual number of such patients had increased either a lot or a little.

Those percentages are respondent-reported survey findings. They are not national incidence estimates, and the two FOI releases should not be treated as independent datasets because their core material overlaps.

Why it matters: The case for regulation is usually argued through known harms. This evidence also shows the cost of not regulating: government cannot consistently count the complications it is trying to prevent.

Already covered: Our Scotland commencement update explains what the 2026 framework activates and what remains on hold.

MHRA enforcement — no new development

No change. A review of the MHRA publications listing through 26 July found no new target-sector clinic-enforcement, illegal-weight-loss-medicine or botulinum-toxin development after the prior scan.

Already covered: On the medicines-approval side, our Wegovy MASH update explains the latest live MHRA development in the CMC library.

The week ahead

Scotland's FOI evidence sharpens the question that should follow licensing legislation: how will complications be recorded consistently once the framework is operating? We will also watch for any English licensing timetable and fresh GPhC, ASA or MHRA action.

Regulatory Pulse publishes every Friday. Weeks with no change get published anyway — because knowing what stayed the same is as valuable as knowing what moved.